Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,516
  • Shares Outstanding, K 7,638
  • Annual Sales, $ 28,520 K
  • Annual Income, $ -40,180 K
  • EBIT $ -45 M
  • EBITDA $ -48 M
  • 60-Month Beta 0.49
  • Price/Sales 3.70
  • Price/Cash Flow N/A
  • Price/Book 3.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.63
  • Number of Estimates 1
  • High Estimate -1.63
  • Low Estimate -1.63
  • Prior Year -1.98
  • Growth Rate Est. (year over year) +17.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.82 +38.39%
on 04/22/25
14.80 -8.14%
on 05/05/25
+3.65 (+36.72%)
since 04/21/25
3-Month
7.75 +75.35%
on 04/07/25
14.80 -8.14%
on 05/05/25
+1.24 (+10.04%)
since 02/21/25
52-Week
7.75 +75.35%
on 04/07/25
19.93 -31.81%
on 09/23/24
-1.57 (-10.36%)
since 05/21/24

Most Recent Stories

More News
Assembly Biosciences: Q1 Earnings Snapshot

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 13.59 (-6.08%)
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

ASMB : 13.59 (-6.08%)
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

ASMB : 13.59 (-6.08%)
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

ASMB : 13.59 (-6.08%)
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

ASMB : 13.59 (-6.08%)
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

ASMB : 13.59 (-6.08%)
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

ASMB : 13.59 (-6.08%)
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

ASMB : 13.59 (-6.08%)
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

ASMB : 13.59 (-6.08%)
Insider Purchase: 10% owner at $ASMB (ASMB) Buys 17,024 Shares

Alexander Schornstein, a 10% owner of $ASMB ($ASMB), bought 17,024 shares of the company on 11-22-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

ASMB : 13.59 (-6.08%)

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

3rd Resistance Point 15.43
2nd Resistance Point 15.07
1st Resistance Point 14.33
Last Price 13.59
1st Support Level 13.22
2nd Support Level 12.85
3rd Support Level 12.11

See More

52-Week High 19.93
Fibonacci 61.8% 15.28
Fibonacci 50% 13.84
Last Price 13.59
Fibonacci 38.2% 12.40
52-Week Low 7.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar